SCHEMBL6134720

SCHEMBL6134720

CCCCCS(=O)(=O)NC(=O)c1ccc2nc(C)n(Cc3ccc(-c4ccccc4)cc3Cl)c2c1

nearest known ligand 0.80

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARG P37231 11/20 0.80
PTPN1 P18031 1/20 0.47
HDAC1 Q13547 2/20 0.45
HDAC6 Q9UBN7 2/20 0.45
HDAC3 O15379 1/20 0.45
HDAC4 P56524 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC10 Q969S8 1/20 0.45
HDAC11 Q96DB2 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC9 Q9UKV0 1/20 0.45
HDAC5 Q9UQL6 1/20 0.45
PTGER4 P35408 1/20 0.41
RORC P51449 1/20 0.40
AGTR1 P30556 1/20 0.39
AGTR2 P50052 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6304186 0.98 PPARG (0.76) PPARGPTPN1HDAC1HDAC6HDAC3
SCHEMBL27448720 0.92 PPARG (0.68) PPARGPTPN1HDAC1HDAC6HDAC3
SCHEMBL7650777 0.92 PPARG (0.91) PPARGHDAC1HDAC6HDAC3HDAC4
SCHEMBL1160303 0.90 PPARG (0.82) PPARGPTPN1HDAC1HDAC6HDAC3
SCHEMBL7652356 0.90 PPARG (0.64) PPARGHDAC1HDAC6HDAC3HDAC4
Atx08-001 SCHEMBL29691565 0.89 PPARG (1.00) PPARGHDAC1HDAC6HDAC3HDAC4
SCHEMBL1160346 0.89 PPARG (0.81) PPARGPTPN1HDAC1HDAC6HDAC3
Atx08-001 SCHEMBL29368164 0.89 PPARG (1.00) PPARGHDAC1HDAC6HDAC3HDAC4
Atx08-001 SCHEMBL682052 0.89 PPARG (1.00) PPARGHDAC1HDAC6HDAC3HDAC4
SCHEMBL1160144 0.89 PPARG (0.81) PPARGPTPN1HDAC1HDAC6HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005082414-A2 CONCOMITANT DRUGS OF A SULFONAMIDE AND ANOTHER THERAPEUTIC AGENT ASTELLAS PHARMA INC. (JP) 2005-09-09 WO claimed
US-20050197376-A1 Concomitant drugs FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-09-08 US claimed
US-6420409-B1 GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US claimed
EP-1020452-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-19 EP claimed
US-20050197376-A1 Concomitant drugs FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-09-08 US disclosed
US-6420409-B1 GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US disclosed
EP-1020452-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-19 EP disclosed